These findings align with the immunometabolic framework, where AMPK regulates energy homeostasis, mitochondrial biogenesis, glucose uptake, lipid oxidation, and inflammatory pathways, offering therapeutic potential for obesity, insulin resistance, type 2 diabetes, cardiovascular diseases, neurodegenerative conditions, NAFLD, and sarcopenia. This evidence concerns the gene PRKAA1 and obesity due to melanocortin 4 receptor deficiency.